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ABSTRACT: Identifying ligand binding sites on proteins is 
a critical step in target-based drug discovery. Current ap-
proaches to this require resource intensive screening of large 
libraries of lead-like or fragment molecules.  Here we describe 
an efficient and effective experimental approach to mapping 
interaction sites using a set of halogenated compounds ex-
pressing paired hydrogen-bonding motifs, termed FragLites. 
The FragLites identify productive drug-like interactions, 
which are identified sensitively and unambiguously by X-ray 
crystallography, exploiting the anomalous scattering of the 
halogen substituent.  This mapping of protein interaction sur-
faces provides an assessment of druggability and can identify 
efficient start points for the de novo design of hit molecules 
incorporating the interacting motifs.  The approach is illus-
trated by mapping cyclin-dependent kinase 2, which success-
fully identifies orthosteric and allosteric sites.  The hits were 
rapidly elaborated to develop efficient lead-like molecules.  
Hence, the approach provides a new method of identifying lig-
and sites, assessing tractability and discovering new leads. 
Introduction 
The identification of ligand binding sites is a critical initial step 
in assessing whether a protein target is amenable to modulation by 
a chemical probe and, ultimately, a drug molecule.1  Binding of a 
small molecule to a specific site preferentially occurs where the 
protein offers a poorly solvated, hydrophobic pocket.2  However, 
for a small molecule to be specific in its interactions (as is required 
for a chemical probe3) as well as possess the necessary physical 
properties to be functional in a biological environment (as is re-
quired for a drug), it must also contain polar groups that may con-
tribute to solubility, modulate pharmacokinetics, and form geomet-
rically constrained, and hence selective, interactions with the pro-
tein.4,5,6  This combination of requirements makes it difficult to pre-
dict the number and location of drug-like compound binding sites 
on a protein from the 3D structure of the protein alone.  The active 
sites of proteins, which are refined by evolution to bind to other 
macromolecules, co-factors or substrates, can generally be recog-
nised from their shape and physicochemical properties.7  Conse-
quently, such sites can, in some cases, be targeted in drug or probe 
discovery campaigns. Allosteric sites or sites of regulatory protein-
protein interaction, by contrast, are harder to identify and harder to 
exploit.8,9  Since the existence of potential binding sites, and their 
propensity to bind drug-like molecules, cannot be known prior to 
commencing investigations, a significant amount of effort is wasted 
in attempting to identify leads against intractable targets. 
Considerable attempts to address this issue have been made us-
ing both computational and experimental methods.  Computational 
methods can provide useful indications of the presence of binding 
sites10 but have, in general, not been accurate enough to be used 
with confidence as a tractability filter.9,11  Experimental methods 
are generally based on screening compounds.  In such a setting, the 
application of screening by NMR12,13 or X-ray14,15,16 based methods 
is attractive, since these techniques can detect the binding of lig-
ands that have relatively low affinity for their target (Kd values up 
to 10 mM).17  X-ray crystallography, in particular, provides an in-
formation rich assessment of binding sites, revealing not only the 
location of the binding site, but also the specific protein-ligand in-
teractions.  Although crystal structures of compounds with very 
small ligands are known, compounds usually need to have a thresh-
old level of affinity to achieve the degree of occupancy to be de-
tected with confidence.  This typically requires compounds of a 
certain size (molecular mass greater than 200 Da) as well as com-
plementarity of shape and pharmacophoric interactions.18,19  
Smaller compounds are likely to bind with lower affinity, hence 
with lower occupancy, and be hard to distinguish from ordered sol-
vent in electron density maps. The number of drug-like molecules 
within the higher mass range is enormous,20,21 consequently librar-
ies that sufficiently cover the corresponding chemical space are 
both large (containing thousands of compounds22) and hard to 
design to populate chemical space systematically.  It would be pos-
sible to cover chemical space far more comprehensively with 
smaller compounds, but such compounds may lack the affinity and 
shape recognisability required for their binding to be unambigu-
ously confirmed by X-ray crystallography. 
A further complication that arises when experimentally assessing 
target tractability is that the observation of molecules bound to a 
protein pocket does not necessarily establish that pocket to be ame-
nable to binding a small molecule that has properties compatible 
with development into a drug or chemical probe.  For this to be the 
case, some of the molecule’s binding affinity must derive from po-
lar interactions, in particular through the formation of hydrogen 
bonds that are energetically more favourable than those it might 
otherwise make with solvent.23  The penalty of desolvation upon 
protein binding for functional groups capable to forming such in-
teractions can be such that they contribute little or nothing to the 
overall binding energy.2  This penalty can be minimised if more 
than one polar interaction can be made by groups on a ligand that 
are in close proximity to one another, such that the combined solv-
ation sphere of the groups is reduced relative to that of the two 
groups in isolation.  Protein – ligand pairs that are capable of mak-
ing such cooperative interactions are likely to have the combination 
of high affinity and relatively low lipophilicity required for a drug 
molecule or chemical probe.22 
   
 
 
Results 
We hypothesised that such potential interacting sites could be 
found by designing a library of molecules of minimal size and com-
plexity, that comprises compounds displaying a combination of two 
functionalities capable of forming hydrogen bonding interactions 
in proximity but with different spatial orientations, termed pharma-
cophore doublets (Fig. 1).  In addition to providing potential for 
polar protein-ligand interactions, the doublet of polar groups would 
be expected to confer a degree of aqueous solubility to library 
members, allowing them to be used at high concentrations in crys-
tallographic and other assay conditions - a requirement because 
molecules of this size are expected to have low affinity for their 
targets.  Presenting these doublets on an aromatic scaffold would 
provide potential for lipophilic interactions and to conform to the 
typical architecture of drug-like molecules. Incorporating a heavy 
halogen atom (bromine or iodine) into each compound would fur-
ther allow unambiguous identification of the position and orienta-
tion of the fragments by detection of a signal in X-ray crystallog-
raphy that arises from the anomalous dispersion of the halogen 
atom.24,25,26  Confidence in this concept was provided by a recent 
paper in which bromo- and iodopyrazole were shown to bind to 
numerous sites on three proteins, with ligand binding occurring at 
known active sites and at previously undescribed allosteric sites.27 
Accordingly, we designed a set of compounds that individually 
display all the combinations of a hydrogen bond donor-acceptor or 
acceptor-acceptor doublet with 1 to 5 bond connectivity between 
them.  We also incorporated some redundancy into the set, popu-
lating the likely more productive combinations such as 1,2 donor-
acceptors and 1,2 acceptor-acceptors multiple times.  This allows 
assessment of reproducibility and incorporates variety in the orien-
tation of the pharmacophore doublet with respect to the halogen.  
This resulted in the selection of a set of 31 compounds that populate 
all combinations of pharmacophore doublets (Fig. 1).  Where not 
commercially available, these molecules were synthesised using 
standard chemistry (see Supporting Information).  We term these 
molecules “FragLites” [defined as small (≤13 heavy atoms) com-
pounds bearing a pharmacophore doublet and a heavy halogen 
atom] due to their minimal size, maximal simplicity and high visi-
bility in X-ray crystallography. 
 
 
Figure 1 – Design of the FragLite set and their matching to phar-
macophore doublets of donors (red) and acceptors (blue) along with 
their halogen tag (green), grouped by the connectivity (number re-
fers to the number of bonds separating the doublet. 
 
To test our hypothesis, each FragLite was soaked into an exem-
plar protein.  The well diffracting system of cyclin-dependent ki-
nase 2 (CDK2) was selected for this initial assessment due to its 
precedent for binding small molecules at the orthosteric site,28 iso-
lated reports of allosteric small molecule binding sites,16,29 the well 
characterised allosteric binding of cyclin modulators and the poten-
tial biological significance of the discovery of new allosteric sites.  
Of the 31 FragLites that were soaked, 9 were observed to bind to 
CDK2 in 6 fully distinct sites (compounds 1, 2, 4, 6, 7, 13, 14, 16 
and 31, Fig. 2).  These include the orthosteric site, a known allo-
steric site29 and 4 previously unidentified allosteric sites.  FragLites 
21, 22, 24 and 30 compromised the crystal and so no diffraction 
could be collected. The remaining compounds gave rise to no iden-
tifiable signal in normal or anomalous scattering electron density 
maps (Fig.2bc). This represents a significant overall hit rate, sup-
porting the hypothesis that the FragLites have general utility as uni-
versal fragments.  
Unambiguous detection of the low affinity binding events was 
achieved by looking for a peak more than 5 standard deviations 
above the mean value in an anomalous Fourier – a Fourier map 
calculated from phased X-ray diffraction data that presents features 
at sites occupied by anomalously scattering atoms.  Whereas all at-
oms display a small amount of anomalous scattering, the magnitude 
of the scattering broadly increases with atomic number, being de-
tectable for atoms with an atomic number greater than 8, depending 
on the wavelength of X-rays used and the signal to noise radio of 
the data collected. 
   
 
 
To evaluate the enhancement in sensitivity provided by the 
anomalous signal, we compared the hit rate achieved using anom-
alous scattering with that achieved using only normal scattering.  
For this purpose, we applied the Pan-Dataset Density Analysis 
(PanDDA) algorithm, a state-of-the art statistical approach for de-
tecting weak binding events in electron density maps.30  The sensi-
tivity of PanDDA derives from building a model for the variance 
of pixels in “apo” electron density maps so that significant devia-
tions can be identified.  Subsequently, the PanDDA algorithm ex-
ploits these variances to optimally subtract a proportion of the con-
founding ground state, thereby revealing a deconvoluted image of 
the ligand-bound state.31  PanDDA analysis was performed on 31 
ligand bound crystal datasets, bootstrapped from a variance model 
made from 43 apo-CDK2 crystal datasets. Through this analysis, 
PanDDA was able to identify 10 of the 16 binding events identified 
through anomalous scattering. Binding events caught by anoma-
lous scattering but missed in the PanDDA analysis involved the 
unique sites observed for 6 and 14 and four of the six binding events 
found for 31.  In addition to highlighting sites that were not picked 
up by PanDDA, the anomalous signal from FragLite molecules 
contributed to the unambiguous determination of binding pose for 
several fragments, including compound 1 (Fig. 2b). While the de-
convoluted PanDDA map was suggestive of a bound molecule, ad-
ditional consideration of the associated anomalous peaks allowed a 
clear identification of two alternate binding modes for the frag-
ment. 
 
Figure 2 – Binding sites of CDK2 revealed by FragLites. a) Over-
view of binding events to CDK2 (white ribbon), depicting the 6 dis-
tinct sites identified by the FragLite library (yellow), PDB codes: 1 
6Q3C, 2 6Q3B, 4 6Q3F, 6 6Q49, 7 6Q48, b 6Q4B, 14 6Q4A, 16 
6Q4C, 31 6Q4D, b) The anomalous signal generated resulting from 
the binding of 1 allows for unambiguous fragment hit identification 
and aids orientation of the two binding modes (b & c). Anomalous 
LLG map (orange surface contoured at 3σ), Weighted map from re-
finement (blue mesh contoured at 1σ). d) Evaluation of the dataset 
through PanDDA, shows native PanDDA event map (green con-
toured at 1σ) allowing identification of both binding modes of 1. e) 
Six additional binding events identified through anomalous signal, 
not identified by PanDDA analysis, 6,14 and  four copies of 31. 
 
The orthosteric (ATP binding) pocket bound seven different 
FragLites, with six (1, 2, 7, 13, 14 and 16) making one or more 
hydrogen bonding contacts with the “hinge” region and 2-methoxy-
4-bromophenyl)acetic acid 31 binding in a distal pocket.  It is well 
established that targeting the ATP-competitive site of CDK2 with 
drug-like small molecules is feasible, with most such molecules 
forming hydrogen bonding interactions with the hinge region.  
Hence, the observation that this region binds the FragLite mole-
cules with the highest frequency establishes that the mapping exer-
cise can successfully identify the most tractable site, and therefore 
contribute to ranking and/or prioritising sites for further investiga-
tion. 
3-Bromopyrazole 1 bound in two subtly different modes, the first 
with the pyrazole 2-nitrogen accepting a hydrogen bond from the 
backbone of Leu83 and the other showed the 2-nitrogen accepting 
a H-bond from Leu83 and the NH forming a H-bond with the back-
bone carbonyl of Glu81 (Fig 3a); 3-iodopyrazole 2 showed the 
same interactions (Supplementary Fig. 1).  4-Iodopyridone 7 also 
formed the donor acceptor paired interaction with the NH and car-
bonyl of Leu83 (Fig. 3b) and both 5-bromopyrimdine 13 and 5-
iodopyrmidine 14 formed a hydrogen bond to the NH and a CH 
hydrogen bond from the pyrimidine 6-hydrogen to the backbone 
carbonyl of Glu81 (Fig. 3c and Supplementary Fig. 2).  Bromo-
naphthyridine 16 bound to the hinge via a halogen mediated inter-
action. 
In addition to the direct interactions with the hinge, (2-methoxy-4-
bromophenyl)acetic acid 31 bound in the ATP-pocket, slightly off-
set from the hinge, with the carboxylate interacting with the back-
bone NH and sidechain hydroxyl of Thr14 and the amino group of 
Lys129, the benzene ring also formed a π-cation interaction with 
Lys33 (Fig. 3d). 
   
 
 
 
Figure 3 – Interactions of FragLites in the ATP pocket. a) 3-bro-
mopyrazole 1, b) 4-iodopyridone 7, PDB code 6Q48, c) 5-bro-
mopyrimidine 13, PDB code 6Q4B, d) (2-methoxy-4-bromo-
phenyl)acetic acid 31, PDB code 6Q4D, e) 4-bromonaphthyridine 
16, PDB code 6Q4C. Protein atoms involved in direct interactions 
are highlighted in bold. The surface colour indicates regions of hy-
drophobicity (green), polarity (red) and solvent exposure (blue). 
Of the five allosteric sites, 2-amino-4-bromopyridine 4 bound in 
the lower region of the C-terminal lobe on the C-helix side (Fig. 2).  
Binding interactions were made by the donation of hydrogen bonds 
from both hydrogens of the amino group to the backbone amide of 
Lys178 and Tyr180, along with π-cation interactions between the 
pyridine ring and Arg126 and Arg150 (Fig. 4a).  A second allosteric 
site at the very bottom of the C-lobe was identified by 4-bro-
mopyridone 6, which formed a hydrogen bond between the car-
bonyl and the backbone NH of Tyr269 as well as a π-cation inter-
action with Arg245 (Fig. 4b). 
The remaining allosteric sites were all identified by (2-methoxy-4-
bromophenyl)acetic acid 31, which bound in three different orien-
tations at a region in the palm of N-terminal lobe, a single location 
below the hinge region and a peripheral site close to the cyclin bind-
ing region (Fig. 2).  Each of these binding events were dominated 
by interactions of the carboxylate group.  In the N-lobe palm, one 
copy formed interactions with the amino groups of Lys34, Lys75 
and Tyr77 (Fig. 4c), a second copy formed an interaction with the 
amino group of Lys6 (Fig. 4d) and the third copy formed hydrogen 
bonds to the backbone NH groups of Glu2, Asn3 and Phe4 (Fig. 
4e).  At the bottom left of the C-lobe, making a single hydrogen 
bond contact to the backbone NH of Leu101 in a relatively solvent 
exposed region (Fig. 4f). 
 
Figure 4 – Interactions of the FragLites in the identified allosteric 
sites. a) 2-amino-4-bromopyridine 4, PDB code 6Q3F, b) 4-bro-
mopyridone 6, PDB code 6Q49, c-f) (2-methoxy-4-bromo-
phenyl)acetic acid 31, PDB code 6Q4D. Protein atoms involved in 
direct interactions are highlighted in bold. The surface colour indi-
cates regions of hydrophobicity (green), polarity (red) and solvent 
exposure (blue). 
Together, the mapping of the ATP pocket identifies several produc-
tive hydrogen bonding interactions that reinforce the conclusion 
that this location is the most druggable site.  Moreover, their prox-
imity suggests that it may be possible to use the results of these 
experiments to design active leads by combining the FragLite sig-
natures into merged fragments.  For example, three hydrogen bond-
ing contacts at the hinge were identified by a combination of 3-
bromopyrazole and 4-iodopyridone, overlaying these structures 
suggested molecules that may exploit all three of these contacts 
simultaneously via a contiguous array of hydrogen bond donor - 
acceptor - donor, each separated by two bonds (Fig. 5a).  Accord-
ingly, we conceived of fragments such as 2,6-diaminopyridine 32, 
and 6-aminopurine 33 that would satisfy this combined pharmaco-
phore. 
Upon soaking into CDK2, both 32 and 33 were observed to make 
all three of the postulated hydrogen bond contacts in a manner that 
directly overlaid with that suggested by the FragLite map (Fig. 5b 
and c).  Moreover, compound 33 showed increased affinity relative 
to the original hit; 33 showed a Kd of 350 μM (ligand efficiency 
0.44) by isothermal calorimetry (ITC).  In contrast, original hits 1 
and 8 showed no detectable binding by ITC at 5 mM, consistent 
with the premise that such small fragments have low affinity (Sup-
plementary Fig. 3).  The affinity of 32 could not be determined due 
to poor solubility.  These results show that the FragLite map can be 
used to effectively design highly ligand efficient fragment-like 
leads in a rational manner without extensive screening; the ligand 
  
    
 
 
 
  
    
 
 
  
  
  
 
  
   
    
 
 
  
 
    
 
 
 
  
    
  
  
   
 
 
efficiency (LE)32 value for 36 is 0.44.  Moreover, the lead structures 
are reminiscent of substructures of known CDK2 ligands, which 
have been optimised into potent compounds.33 
 
Figure 5 – Fragment merging from FragLites to produce fragment 
leads. a) 3-point pharmacophore derived from two FragLites bind-
ing to the hinge, b) 2,6-diaminopyridine 32 fulfilling the 3-point 
pharmacophore and making the predicted interactions, PDB code 
6Q4F, c) 4-iodo-6-aminopurine 33 making the predicted interac-
tions, PDB code 6Q4E, with a measurable a Kd by ITC. 
The observation of (2-methoxy-4-bromophenyl)acetic acid 31 
binding in the ATP pocket adjacent to the hinge provided further 
opportunities for increasing potency by fragment growing (Fig. 6a).  
The analysis of FragLite binding suggested it was the carboxylate 
of 31 that made the critical interactions and its orientation sug-
gested that it could be linked to hinge binding Fragments via a di-
rect bond or a single atom linker.  Accordingly, compounds 34 and 
35, combining this template with the hinge binders 7 and 13 as well 
as biarylether 36 and biaryl 37 incorporating the merged amino-
purine motif revealed in 31, were designed. 
Pyrimidine 34 was prepared in a single step SNAr displacement of 
4-bromopyrimidine with (3-aminophenyl)acetic acid (Scheme 1a).  
Pyridone 35 was prepared by copper catalyzed etherification of 4-
bromo-2-methoxypyridine with methyl (4-hydroxyphenyl)acetate 
followed by global demethylation with pyridine hydrochloride 
(Scheme 1b).Compound 36 was synthesised from 6-chloro-9H-pu-
rin-2-amine by bis-dihydropyran protection followed by stepwise 
SNAr substitutions of the chloro-substituent with DABCO, fol-
lowed by methyl 2-(3-hydroxyphenyl)acetate and subsequent ester 
hydrolysis (Scheme 1c).  Compound 37 was also prepared from bis-
tetrahydropyranyl-protected 6-chloro-9H-purin-2-amine by Su-
zuki-Myaura coupling with ethyl 2-(3-(tetramethyldioxaborola-
nyl)phenyl)acetate followed by acidic deprotection (Scheme 1d). 
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Scheme 1 – Synthesis of merged FragLites. a) 34, reagents and con-
ditions: i) (3-aminophenyl)acetic acid, DMF, 80 °C; b) 35, reagents 
and conditions: i) methyl (4-hydroxyphenyl)acetate (1.5 eq.), 
3,4,7,8-tetramethylphenanthroline (cat.), CuI (cat.), Cs2CO3, tolu-
ene, 110 °C, 24h; ii) pyridine hydrochloride (5 eq.), 180 °C; c) 36, 
reagents and conditions: i) dihydropyran (10 eq.), aq. 2M HCl 
(cat.), DCM, r.t., 16h; ii) DMSO, DABCO (2 eq.), r.t., 3h; iii) 1) 
methyl 2-(3-hydroxyphenyl)acetate (1.33 eq.), DBU (1.1 eq.), 
DMF, 65°C, 72h; 2) aq. 2M HCl, THF, r.t., 4h; d) 37, reagents and 
conditions: i) dihydropyran (10 eq.), HCl (2M, cat.), DCM, r.t., 
16h; ii) ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetate (2.5 eq.), K2CO3 (2.5 eq.), Pd(PPh3)4 (0.05 eq.), 
DMF:H2O (1:1), 140 °C, 20', MW hv; iii) aq. 2M HCl, THF, r.t., 
2h. 
Crystallisation of expanded structures pyrimidine 34 and pyridone 
35 revealed their binding mode to be as predicted by the FragLite 
mapping.  The pyrimidine of 34 and pyridone of 35 engaged the 
hinge region with the same interactions as 13 and 7 respectively 
and carboxylate 31 binding to Lys129 with good overlay with the 
original hits (Fig. 6b and c).  Aminopurines 36 and 37 also bound 
in the manner predicted by the FragLite map, with the carboxylate 
and the hinge motifs of the combined fragments making the same 
interactions with the same orientations as the merged fragment 33 
and original hit 31 (Figure 6d and e).  Compound 36 did not show 
a binding isotherm by ITC, however, 37 demonstrated concentra-
tion dependent binding in ITC with a Kd of 50 μM, equivalent to a 
ligand efficiency of 0.30 (Fig. 6e).  These results demonstrate that 
the FragLite mapping can be used to efficiently inform fragment 
growing strategies to derive lead molecules with promising binding 
affinity in short order without the synthesis of large numbers of an-
alogues. 
 
 
 
 
 
 
   
  
  
        
     
     
     
   
  
 
 
 
 
 
 
 
     
         
 
 
 
 
 
  
  
           
         
   
 
 
  
Figure 6 – Linking hinge binding compounds with carboxylate con-
taining FragLite 31. a) Overlay of 33 (grey carbon atoms), indicat-
ing orientation of the hinge motif, and 31 (cyan carbon atoms) as 
they bind to the CDK2 ATP pocket, b) Linked aminopyrimidine 34 
binding to CDK2 and forming interactions with the hinge and 
Thr14, PDB code 6Q4J, overlay shows the alignment of 34 (grey) 
with the original hits 13 and 31 (cyan), c) Linked pyridone 35 bind-
ing to CDK2, PDB code 6Q4I, with 34 (grey) overlaid with 7 and 
31 (cyan), d) Linked pyridone biarylether 36 (grey) binding with 
the acid making comparable interactions to 31 (cyan), PDB code 
6Q4H, e) Linked biarylether 37 (grey) binding to CDK2making 
comparable interactions to 31 (cyan), PDB code 6Q4G, and demon-
strating concentration dependent binding by ITC. 
In addition to the hinge interactions, to illustrate that follow up hit 
development for the allosteric pockets was also possible, we stud-
ied further analogues of (2-methoxy-4-bromophenyl)acetic acid 31 
to investigate their propensity to bind to the same allosteric pockets.  
This investigation revealed that amide substituted cinnamic acid 38 
was able to bind to the site identified by 31 at the bottom of the C-
lobe (Fig. 4f).  In this case, the carboxylate does not make the same 
interactions in the analogue but the distal p-chlorophenyl ring over-
lays with the aromatic ring of 31, in the lipophilic region of this 
relatively polar pocket (Fig. 7).  This observation suggests that the 
FragLite mapping identifies tractable allosteric sites for which op-
timisable leads can be identified.  It also suggests that the lipophilic 
scaffolds employed in the design of the FragLites, in addition to the 
polar hydrogen bonding pairs, are important for binding, and that 
the combination of the two is essential for identifying tractable 
sites. 
 
Figure 7 – Cinnamic acid fragment 38 binding to the allosteric 
pocket at the bottom of the C-lobe, PDB code 6Q4K. 
Discussion 
The key principle of fragment screening is to screen smaller com-
pounds to cover more chemical space with fewer compounds than 
traditional lead-like libraries.  The smaller the compounds, the 
fewer will be required to fully cover chemical space.  FragLites 
provide the smallest possible constructs that can display hydrogen-
bonding doublet on aromatic scaffolds.  The hit rate for binding to 
CDK2 (8/31, 26%) is considerably higher than could be expected 
for the hit rate in a screen of fragments, which is typically around 
5%.19  This hit rate far exceeds that observed previously for frag-
ment screening against CDK2 with regard to hit rate34 and the num-
ber of identifiable sites.29  This provides evidence that FragLites 
provide much more extensive coverage of chemical space with 
fewer compounds than is possible with compound libraries of 
larger molecules. 
Our results demonstrate that FragLite mapping of a protein pro-
vides accurate experimental identification of productive ligand 
binding sites.  The observation that the frequency of FragLites 
binding to the region established to be most druggable (the ATP 
pocket binds 6/31 compounds) and that the majority of these (5/31) 
make the well characterised hydrogen bonding interactions with the 
hinge gives confidence that this exercise can be used as an experi-
mental druggability assessment.  The identification of additional 
pockets, one of which we have shown, with very limited follow up 
to be amendable to binding traditional fragments, suggests that the 
analysis can also be used to identify novel allosteric pockets. 
The points of interaction identified by the FragLites could be used 
prospectively to define a pharmacophore for virtual screening or to 
focus future library chemistry.  For example, in our CDK example, 
further molecules could be selected satisfying the three-point hy-
drogen bonding pharmacophore identified at the CDK2 hinge cou-
pled with the interaction made by the carboxylate.  This is potential 
advantage of this approach in that it can identify productive inter-
actions within a tractable pocket (and presumably not unproductive 
  
   
 
  
  
   
 
 
ones) to focus future hit finding.  Other approaches, such as com-
putational druggability calculations are unable to do this with con-
fidence. 
Furthermore, the results of fragment merging leading to hit-like 
levels of affinity and high ligand efficiency demonstrate that the 
FragLite map can be used in hit generation directly, without re-
course to further hit generation activities.  We would not contend 
that this approach renders further screening unnecessary but could 
be applied if further screening approaches are unavailable or re-
source limited.  The short order in which we were able to produce 
potent merged fragments demonstrates that this can be a very effi-
cient way to find hit compounds. 
A further extension of this work would be to investigate why cer-
tain residues within proteins are more able to form productive polar 
interactions such as hydrogen bonds when others are not.  Why, for 
example, are the hydrogen bonding interactions with the peptide 
backbone in the hinge region identified when other backbone inter-
actions are not?  This particular case is well established with almost 
all kinase inhibitors requiring hydrogen bonding to the hinge region 
to achieve potency.35 
The incorporation of the halogen atom is essential to this approach.  
Without the analysis of anomalous scattering, it would not be pos-
sible to determine the location and orientation of the hits.  Another 
potential advantage of the incorporation of an anomalous scatter is 
their use in weaker diffracting crystal systems, to help resolve am-
biguity of binding events. When reviewing the crystallographic 
binding event data, consideration was given to the generation of 
halide ions from the compound upon exposure to synchrotron radi-
ation.36,37,38  In some instances, we observed anomalous signal for 
a liberated halide ion but this was of no consequence for the analy-
sis.  The degree of radiation damage can be minimised by control-
ling the radiation energy. 
The PanDDA analysis method for identification of low occupancy 
ligands identified the majority of those detected using the anoma-
lous signal but failed to identify the binding events of two FragLites 
and several of the binding sites of FragLite 31.  Increasing ligand 
occupancy would require screening at much higher concentrations 
at which many of the desired compounds would be insoluble.  Sim-
ilarly, use of an anomalous signal may allow for application to 
weakly diffracting crystal systems, which are typically not suitable 
for a fragment crystallography campaign. 
The FragLite mapping can be carried out very rapidly, due to the 
small number of compounds required.  Our selected set can be 
soaked into protein crystals in a single experiment and X-ray dif-
fraction data on the entire set collected within a day.  Critical to the 
further development of this approach is the definition of the opti-
mum set of compounds that cover chemical space most effectively 
with the minimal number of compounds.  Our work shows that ad-
ditional information can be obtained, at least for CDK2, by screen-
ing a larger compound set than that explored by Arnold.27  It is 
noteworthy, however, that bromo- and iodopyrazole, the most pro-
miscuous compounds in Arnold’s experiment, have also proven to 
be the most useful here.  We contend that this is likely due to that 
fact that the 1,2-donor-acceptor motif can form highly productive 
complementary hydrogen bonds with a protein target.  This obser-
vation could be useful for future ligand design.  This work also sug-
gests that the promiscuous carboxylate 31 may offer an alternative 
“universal fragment” that could be used for SAD phasing as estab-
lished by Arnold for bromopyrazole. 
Despite these results, we believe that the definition of the optimal 
set of FragLites that strike the best balance between minimising the 
numbers of compounds to screen and maximising the coverage of 
chemical space will require further optimisation across a wide 
range of proteins and larger number of compounds.  Our results 
suggest that some redundancy in the screening set is required.  
There are differences between the binding of analogous brominated 
and iodinated FragLites and not all the hits expressing the same 
pharmacophore doublet bind in the same manner.  Perhaps most 
strikingly, it is surprising that 4-bromo-2-aminopyridine 4 was not 
detected binding to the hinge region and 4-iodo-2-aminopyridine 5 
did not bind at all.  These compounds express the same 1,3-donor-
acceptor doublet as 4-iodopyridone 7 which made the critical pair 
of H-bonds in the hinge region.  It is possible that the geometry of 
the bound pose required for 4 and 5 to bind to the hinge is incom-
patible with accommodation of the heavy halogen atom.  Con-
sistent with this theory, 4-chloropyridine did bind at the hinge in 
the manner that was predicted by the binding mode of 7 (Supple-
mentary Fig. 4).  This suggests that the ideal set should cover a 
range of differing geometries between the pharmacophore doublets 
and the halogen atom.  Future work will explore these observations 
further to define the optimal FragLite set. 
Conclusion 
The definition of the set of 31 FragLites and mapping of CDK2 
protein to identify the most tractable, orthosteric site and exploita-
ble allosteric sites suggest that FragLites offer a new approach to 
assessment of druggability that provides a facile and informative 
hit-finding activity.  Development of potent hit compounds directly 
from the FragLite map shows that the information can also be used 
for hit-finding in isolation.  We believe that this has the potential to 
be a nuanced approach to hit finding that will supplement and in-
form screening of more traditional fragment and lead-like libraries. 
Future work will explore the application of this approach to a wider 
range of proteins and with a wider range of designed FragLites.  
This will establish the general applicability of the approach and op-
timise the compound set for prospective screening.  The results of 
these studies will be reported in due course. 
Experimental Section 
Protein Purification 
Full length human CDK2 for crystallography was cloned into a 
pGEX6P1 vector (GE Healthcare) and grown in BL21(DE3)STAR 
Escherichia coli (E. coli) cells.39 For ITC, full length human CDK2 
was cloned into a modified pGEX3C plasmid40 containing Saccha-
romyces cerevisiae Civ1 for activation loop T160 phosphorylation 
and grown in BL21(DE3)pLysS cells.  
All E. coli were then grown at 37 ⁰C until an optical density of 0.4-
0.6 before decreasing the temperature to 18 ⁰C with 0.2 mM IPTG 
(Isopropyl β-D-1-thiogalactopyranoside; Sigma) induction for 
BL21(DE3)STAR and Rosetta(DE3)pLysS cells. 
BL21(DE3)pLysS cells were grown in auto-induction media 
(Formedium) and so didn’t require induction with IPTG. All other 
constructs were grown in Luria Broth (LB; Invitrogen). All cells 
were incubated for a further 16-20 hours at 18 C, before harvesting 
via centrifugation (4,000 xg, 30 mins, 4 ⁰C) and resuspension in 50 
mM HEPES, 150 mM NaCl, 2 mM DTT (dithiothreitol), pH 7.4 
and EDTA (ethylenediaminetetraacetic acid)-free protease inhibi-
tor tablets (Roche). For lysis, cell suspensions were then supple-
mented with 2 μg/mL DNase I, 10 μg/mL RNase A, 25 μg/mL ly-
sozyme and 5 mM MgCl2 before pulsed sonication for 5 mins (20 s 
   
 
 
on, 40 s off) on ice. Cell lysates were then recovered via centrifu-
gation (40, 000 xg, 60 mins, 4 ⁰C) before 0.45 μm filtering and 
batch binding to glutathione sepharose 4B resin (GE Healthcare) 
for 60 mins, 4 ⁰C with rolling. Batch-bound lysate was then poured 
down a gravity flow column, with GST-CDK2 (all constructs are 
GST-fusions) eluted from the resin using 50 mM HEPES, 150 mM 
NaCl, 2 mM DTT, 10 mM reduced glutathione, pH 7.4. GST was 
then cleaved from CDK2 using 1:100 w/w 3C prescission protease 
overnight at 4 ⁰C with rolling. Protein was then separated from GST 
using gel filtration (26-60 HiLoad Superdex 75 preparative grade 
(GE Healthcare)) before subtractive GST using a 5 mL GSTrap fast 
flow column (GE Healthcare). 
For the phosphorylated CDK2 construct (used for ITC experi-
ments), protein was then concentrated appropriately using a Milli-
pore spin concentrator and flash frozen using liquid nitrogen for 
storage at -80 ⁰C 
For crystallisation, CDK2 was then buffer exchanged into 100 mM 
4:1(Dibasic:monobasic) K2:Na phosphate, 2 mM DTT buffer and 
concentrated to 10 mg/mL prior to crystalisation.41  
Crystallisation and structure determination 
Crystals of CDK2 protein were prepared using the hanging drop 
vapour diffiusion method. Protein was mixed 1:1 with precipitant 
solution (6% PEG3350, 100 mM HEPES pH 7.4) over a reservoir 
of 50 mM HEPES pH 7.4, 25 mM K2HPO4, 25 mM NaH2PO4. 
Crystals were then soaked for 48 hours in 50 mM compound pre-
pared to 10 % DMSO in CDK2 precipitant solution (6% PEG3350, 
100 mM HEPES pH 7.4). Crystals were then harvested in 30 % 
ethylene glycol prepared in CDK2 precipitant solution and flash-
cooled in liquid nitrogen. 
X-ray diffraction data were then recorded either at Diamond Light 
Source, Oxford, UK or in house using a rotating copper anode X-
ray source. Structural data were determined using the CCP4 suite 
of programs.42 Data were firstly processed using DIALS and XDS 
43 within Xia2.44 The structures were solved using molecular re-
placement using PHASER45 and protein databank (PDB) code 
1HCK46 as a search model. Refinement was carried out using 
REFMAC5,47 with model building performed and compound de-
scriptions generated using COOT48 and AceDRG,49 respectively. 
Figures were prepared using the CCP4 molecular graphics pro-
gramme CCP4mg50 and MOE (Molecular Operating Environment, 
2013.08; Chemical Computing Group ULC, 1010 Sherbooke St. 
West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018). 
PanDDA (Pan-Dataset Density Analysis)30 was undertaken using 
31 FragLite datasets against a variance model derived from 42 apo 
CDK2 crystal datasets. Derived PanDDA maps were analysed us-
ing the panda.inspect command and results tabulated appropriately. 
Isothermal Titration Calorimetry (ITC) 
CDK2 was buffer exchanged using a 5 mL HiTrap desalting col-
umn (5 mL) (GE Healthcare) into ITC buffer (50 mM HEPES, 150 
mM NaCl, 0.25 mM TCEP, pH 7.4) and protein concentration was 
then determined using a Nanodrop 2000 at an absorbance of 280 
nm. with sequence derived extinction coefficients 
(http://web.expasy.org/protparam/). Protein was prepared in ITC 
buffer, with 1 % DMSO in the cell at 20  M with compounds pre-
pared at 5 mM or 1 mM in ITC buffer at 1 % DMSO final, in the 
syringe. 
All ITC experiments were carried out at 30 C using a Microcal 
PEAQ ITC instrument (Malvern) with 1× injection of 0.4  L for 
0.8s followed by 19× 2  L, 4s injection with 120 s spacing between 
injections, using a reference power of 6  cal/s. Data were then an-
alysed using Malvern Microcal PEAQ-ITC analysis software using 
a one-set-of-sites model. Data analysis was also conducted at low-
c51,52 so, in accordance with the crystallographic evidence, stoichi-
ometry was set at n=1 set of sites, during fitting. Data was analysed 
using Microcal PEAQ Evaluation software (Malvern) using the one 
set of sites model to calculate the dissociation constant and the error 
of the fit.  Experiments were carried out twice with two separate 
biological preparations of CDK2. 
Chemical Synthesis 
All compounds had purity ≥95% as determined by HPLC (UV de-
tection) and 1H NMR analysis. 
Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30, 31, 32 are commercially 
available. 
4-Bromo-1-(2-hydroxyethyl)pyridin-2(1H)-one (28) 
2-Bromoethanol (326 µL, 4.6 mmol) was added dropwise to a mix-
ture of potassium carbonate (1.59 g, 11.5 mmol) and 4-bromo-
2(1H)-pyridinone (0.20 g, 1.1 mmol) in anhydrous THF (10 mL) 
under nitrogen. The mixture was stirred at 80 ºC for 16 h, allowed 
to cool to room temperature, the precipitate filtered off and the fil-
trate evaporated in vacuo. The crude residue was purified by flash 
column chromatography (EtOAc:MeOH 9:1) to afford 28 (94 mg, 
38%) as a white solid. 
Rf 0.33 (100% EtOAc); mp. 134-135 ºC; IR: νmax 3293, 3039, 2943, 
1629 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 7.2 Hz, 1H), 
6.87 (d, J = 2.2 Hz, 1H), 6.38 (dd, J = 7.2, 2.2 Hz, 1H), 4.14-4.08 
(m, 2H), 3.96 (q, J = 5.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 
162.2, 138.4, 136.0, 123.0, 110.5, 61.5, 52.9; HRMS-ESI (m/z): [M 
+ H]+ C7H9BrNO2+, 217.9811; found 217.9806. 
4-Bromo-1-(2-methoxyethyl)pyridin-2(1H)-one (29) 
2-Bromoethyl methyl ether (216 µL, 2.3 mmol) was added drop-
wise to a mixture of potassium carbonate (0.95 g, 6.9 mmol) and 4-
bromo-2(1H)-pyridinone 6 (0.20 g, 1.1 mmol) in anhydrous MeCN 
(10 mL) under nitrogen. The mixture was stirred at 80 ºC for 16 h, 
allowed to cool to room temperature, the precipitate filtered off and 
the filtrate evaporated in vacuo. The crude residue was purified by 
flash column chromatography (EtOAc 100%) to afford 29 (119 mg, 
45%) as a brown oil. 
Rf 0.25 (1:1 Petrol Ether:EtOAc); IR νmax 2891, 1625, 1111 cm-1; 
1H NMR (500 MHz, CDCl3) δ  7.23 (d, J = 7.2 Hz, 1H), 6.84 (d, J 
= 2.2 Hz, 1H), 6.32 (dd, J = 7.2, 2.2 Hz, 1H), 4.12-4.12 (m, 2H), 
3.64-3.68 (m, 2H), 3.30 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
161.3, 138.8, 135.7, 122.7, 109.7, 70.1, 59.0, 49.4; HRMS-ESI 
(m/z): [M + H]+ C8H11BrNO2+, 231.9968; found 231.9966. 
6-Iodo-9H-purin-2-amine (33) 
Hydroiodic acid (5 mL, 47% aqueous) was added to 2-amino-6-
chloropurine (0.42 g, 2.49 mmol) at 0 °C. The mixture was stirred 
at 0 °C for 8 hours, treated with 5 mL of deionised water at 5 °C 
for 1 hour. The precipitate was filtered and washed with water three 
   
 
 
times. The filter cake was transferred to a 50 mL round bottom flask 
and of 6 M NaOH aqueous solution was added to the solid. The 
solution obtained was added slowly to a solution of acetic acid in 
water (2:25, 27 mL). The resulting suspension was stirred at room 
temperature for 2 h. The solid was collected by filtration, washed 
with water (2 × 5 mL), followed by petrol (5 mL). The solid was 
dried in vacuo to afford 33 (501 mg, 77%) as a yellow powder. 
Rf 0.21 (DCM:MeOH 9:1); mp. 230-231 ºC; IR: νmax 3488, 3293, 
3170 cm-1; 1H NMR (500 MHz, (CD3)2SO) δ 12.81 (br s, 1H), 8.05 
(s, 1H), 6.67 (s, 2H); 13C NMR (125 MHz, (CD3)2SO) δ 160.1, 
151.8, 141.2, 130.5, 122.4; HRMS-ESI (m/z): [M + H]+ C5H5IN5+, 
261.9584; found 261.9582. 
2-(3-(Pyrimidin-4-ylamino)phenyl)acetic acid (34) 
4-Chloropyrimidine (100 mg, 0.87 mmol), 2-(3-aminophenyl) ace-
tic acid (100 mg, 0.66 mmol) and DMF (4 mL) were stirred at 80 ºC 
for 3 h. The mixture was evaporated in vacuo and the crude product 
was purified by flash column chromatography (silica, 
DCM:MeOH:AcOH, 8:2:0.05) to afford 34 (15 mg, 10%) as a 
beige solid.  
 Rf 0.47 (DCM:MeOH:AcOH 9:1:0.05); mp. 186-190 ºC; IR: νmax 
3045, 2827, 1649, 1580, 1516, 1474 cm-1; 1H NMR (500 MHz, 
(CD3)2SO) δ 12.40 (br s, 1H), 9.89 (s, 1H), 8.65 (s, 1H), 8.28 (s, 
1H), 7.63 (d, J = 7.8 Hz, 1H), 7.53 (s, 1H), 7.28 (t, J = 7.8 Hz, 1H), 
6.95 (d, J = 7.8 Hz, 1H), 6.85 (d, J = 5.7 Hz, 1H), 3.56 (s, 2H); 13C 
NMR (125 MHz, (CD3)2SO) δ 159.9, 158.0, 155.1, 139.6, 128.6, 
123.5, 120.6, 118.2, 107.2, 41.0 (Cq absent –CO2H); HRMS-ESI 
(m/z): [M + H]+ C12H11N3O2+ , 230.0924; found 230.0925. 
Methyl 2-(4-((2-methoxypyridin-4-yl)oxy)phenyl)acetate 
4-Bromo-2-methoxypyridine (1.2 g, 6.4 mmol), 3,4,7,8-tetra-
methylphenantroline (139 mg, 0.59 moles), copper (I) iodide (54 
mg, 0.28 mmol), caesium carbonate (2.9 g, 8.9 mmol) and me-
thyl(4-hydroxyphenyl)acetate (1.5 g, 9.0 mmol) in toluene (12 mL) 
were stirred in a sealed tube under nitrogen atmosphere at 120 ºC 
for 3 days. The mixture was allowed to cool to room temperature, 
treated with water (12 mL) and extracted three times with EtOAc. 
The combined organic extracts were washed with brine, dried over 
sodium sulfate, filtered, and concentrated in vacuo. The crude res-
idue was purified by flash column chromatography (silica; EtOAc: 
Petrol Ether 1:9 to 10:0) to afford the desired product (351 mg, 
10%) as a pale yellow oil.  
Rf 0.72 (EtOAc:Petrol Ether 9:1); 1H NMR (500 MHz, CDCl3) δ 
8.03 (d, J = 5.9 Hz, 1H), 7.32 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 8.5 
Hz, 2H), 6.54 (dd, J = 5.9, 2.1 Hz, 1H), 6.18 (d, J = 2.1 Hz, 1H), 
3.91 (s, 3H), 3.72 (s, 3H), 3.64 (s, 2H); 13C NMR (125 MHz, 
CDCl3) δ 171.8, 167.0, 165.9, 153.3, 147.8, 131.0, 120.9, 107.4, 
97.5, 53.8, 52.1, 40.5 (Cq absent). 
2-(4-((2-Oxo-1,2-dihydropyridin-4-yl)oxy)phenyl)acetic acid 
(35) 
 Pyridine hydrochloride (146 mg, 1.2 mmol) and methyl 2-(4-((2-
methoxypyridin-4-yl)oxy)phenyl)acetate (57 mg, 0.2 mmol) were 
combined and the mixture was stirred at 120 ºC until full conver-
sion was observed by TLC. The mixture was allowed to cool to 
room temperature and purified by flash column chromatography 
(C18 silica, CH3CN:H2O 1:9 to 2:3) to give 35 (19 mg, 37%) as a 
beige solid. 
 Rf 0.61 (DCM:MeOH 9:1); mp. 260-261 ºC; IR: νmax 3443, 1613, 
1216, 1182 cm-1; 1H NMR (500 MHz, (CD3)2SO) δ 11.35 (s, 1H), 
7.36 (d, J = 7.3 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.4 
Hz, 2H), 5.97 (dd, J = 7.3, 2.5 Hz, 1H), 5.31 (d, J = 2.5 Hz, 1H), 
3.53 (s, 2H); 13C NMR (125 MHz, (CD3)2SO) δ 172.7, 167.7, 
163.6, 151.6, 136.7, 132.8, 131.2 (×2), 120.7 (×2), 100.5, 98.6 (Cq 
absent); HRMS-ESI (m/z): [M+H]+ C13H11NO4+, 246.0688; found 
246.1010. 
6-chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine 
3,4-Dihydropyran (2.7 mL, 29.5 mmol) was added to 6-chloro-2-
aminopurine (1 g, 2.95 mmol) in anhydrous DMF (50 mL) fol-
lowed by the addition of aqueous hydrochloric acid (50 μL, 5.7 M). 
The mixture was stirred at 60 ºC for 2 h. The mixture was evapo-
rated in vacuo and the crude product was purified by flash column 
chromatography (silica, EtOAc:Petrol Ether 2:3) to afford the de-
sired product (1.55 g, 78%) as a pale yellow oil that crystallised 
upon freezing.  
Rf 0.44 (100% EtOAc); mp. 171-174 ºC; IR: νmax 3269, 2940, 2855, 
1716, 1614 cm-1; 1H NMR (500 MHz, (CD3)2SO) δ 8.42 (s, 1H), 
8.14 (br s, 1H), 5.53 (d, J = 10.2 Hz, 1H), 5.20-5.12 (m, 1H), 4.02 
(d, J = 11.1, 1H), 3.84 (d, J = 11.1 Hz, 1H), 3.46 (td, J = 2.8, 11.1 
Hz, 1 H), 2.21-2.35 (m, 1H), 2.03-1.34 (m, 11H); 13C NMR (125 
MHz, (CD3)2SO) δ 158.1, 153.7, 150.0, 142.3, 124.7, 81.6, 80.4, 
68.2, 66.0, 30.7, 30.1, 30.0, 25.4, 24.9, 22.9; HRMS-ESI (m/z): [M 
+ H]+ C15H21ClN4O2+ 338.1378; found 338.1378. 
Methyl 2-(3-((9-(tetrahydro-2H-pyran-2-yl)-2-((tetrahydro-
2H-pyran-2-yl)amino)-9H-purin-6-yl)oxy)phenyl)acetate 
DABCO (88 mg, 0.59 mmol) was added to a mixture of 6-chloro-
N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (100 mg, 
0.30 mmol) and anhydrous DMSO (3 mL). The mixture was stirred 
at room temperature for 3 h. The mixture was added to a stirred 
suspension of DBU (49 µL, 0.33 mmol) and methyl 2-(3-hydroxy-
phenyl)acetate (98 mg, 0.40 mmol) in anhydrous DMF (2 mL). The 
mixture was stirred at 65 ºC for 72 h. The mixture was treated with 
aqueous saturated sodium bicarbonate (8 mL) and was extracted 
three times with EtOAc and the combined extracts washed three 
times with brine, dried over sodium sulfate, filtered, and concen-
trated in vacuo to give the crude product (145 mg) which was used 
as such in the next step without further purification. 
2-(3-((2-Amino-9H-purin-6-yl)oxy)phenyl)acetic acid (36) 
The crude methyl 2-(3-((9-(tetrahydro-2H-pyran-2-yl)-2-((tetrahy-
dro-2H-pyran-2-yl)amino)-9H-purin-6-yl)oxy)phenyl)acetate (142 
mg, 0.3 mmol) was dissolved in THF (5 mL) and 2M aqueous HCl 
(2.5 mL) and stirred at room temperature for 4 h. The mixture was 
evaporated in vacuo and the crude product was purified by reverse 
phase chromatography (C18 silica, water:CH3CN:NH4OH 
70:30:0.1) to afford 36 (8 mg, 10%) as a white powder. 
 Rf 0.18 (DCM:MeOH 9:1); mp. 284-285 ºC; IR: νmax 1233, 1265, 
1376, 1568 cm-1; 1H NMR (500 MHz, CD3OD) δ 7.97 (s, 1H), 7.38 
(t, J = 8.1 Hz, 1H), 7.27-7.21 (m, 2H), 7.11 (dd, J = 8.1, 1.1 Hz, 
1H), 3.60 (s, 2H); 13C NMR (125 MHz, (CD3)2SO) δ 173.2, 160.22, 
160.18, 153.0, 138.2, 129.6, 126.5, 122.8, 120.2, 41.9 (2 Cq and 1 
Ct absent)*; HRMS-ESI (m/z): [M + H]+ C15H14N3O3+ 286.0935; 
found 286.0931. 
   
 
 
*Weak signals at 139.8 ppm and 159.7 ppm were assigned by 
HMBC but are not sufficiently resolved. 
2-(3-(2-Amino-9H-purin-6-yl)phenyl)acetic acid (37) 
A mixture of 6-chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-pu-
rin-2-amine (100 mg, 0.3 mmol), potassium carbonate (102 mg, 
0.74 mmol), ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetate (86 mg, 0.3 mmol), tetrakis(tri-
phenylphosphine)palladium(0) (17 mg, 0.015 mmol), DMF (1.5 
mL) and deionised water (1.5 mL) was stirred at 140 ºC for 30 
minutes under microwave irradiation under nitrogen. The mixture 
was treated with deionised water (5 mL), extracted three times with 
EtOAc and the combined extracts washed with brine, dried over 
sodium sulfate, filtered, and concentrated in vacuo. The crude res-
idue was dissolved in THF (5 mL) and 2M aqueous HCl (2.5 mL) 
and stirred at room temperature for 4 h. The mixture was neutral-
ised with 2M aqueous NaOH, extracted three times with EtOAc, 
and the combined extracts washed with brine, dried over sodium 
sulfate, filtered, and concentrated in vacuo to give a yellow oil that 
was triturated with anhydrous methanol (5 mL) to afford 37 (5 mg, 
6%) as a white powder.  
 Rf 0.2 (DCM:MeOH 9:1); mp. 329-330 ºC; IR: νmax 3380, 3163, 
3041, 2113, 1911, 638 cm-1; 1H NMR (500 MHz, (CD3)2SO) δ 8.58 
(d, J = 7.4 Hz, 1H), 8.50 (br s, 1H), 8.10 (s, 1H), 7.48 (t, J = 7.4 Hz, 
1H), 7.40 (d, J = 7.4 Hz, 1H), 3.69 (s, 2H); 13C NMR (125 MHz, 
(CD3)2SO) δ 174.8, 156.8, 148.6, 137.8, 135.5, 131.7, 130.6, 
129.5, 41.5 (4 Cq absent)*; HRMS-ESI (m/z): [M + NH4]+ 
C13H12N5O2 + NH4 287.3025; found 287.1240. 
*Weak signals at 123.5 ppm and 159.7 ppm were assigned by 
HMBC but are not sufficiently resolved. 
3-Bromo-N-(4-chlorophenyl)benzamide 
3-Bromobenzoic acid (400 mg, 2.00 mmol) was added to DMAP 
(242 mg, 1.83 mmol) in anhydrous DCM (20 mL), followed by the 
addition of EDC.HCl (460 mg, 2.40 mmol). After 15 min, a solu-
tion of 4-chloroaniline (280 mg, 2.20 mmol) in anhydrous DCM (5 
mL) was added, and the mixture was stirred at rt. for 18 h. Water 
(10 mL) was added to quench the reaction, the organic layer sepa-
rated and washed with 1.0M aqueous HCl (3 × 10 mL). The com-
bined organic layers were dried over magnesium sulfate and the 
solvent concentrated in vacuo. Purification by flash chromatog-
raphy (silica; 0-40% ethyl acetate in petrol ether) afforded the title 
compound as a white solid (270 mg, 87%). 
Rf 0.78 (33% EtOAc:Petrol); mp. 136.0-138.7 ºC; UV λmax (EtOH) 
274 nm; IR νmax 3361, 2112, 1652, 1595, 1517, 1397 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.34-7.31 (m, 2H), 7.36 (d, J = 8.0 Hz,  1H), 
7.59-7.56 (m, 2H), 7.67 (ddd, J = 1.0 Hz, 2.0 Hz, 8.0 Hz, 1H), 7.76 
(dd, J = 1.0 Hz, 8.0 Hz, 1H), 7.83 (br s, 1H), 7.98 (dd, J = 2.0 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 164.3, 136.6, 136.1, 135.0, 
130.4, 130.2, 130.0, 129.2, 125.6, 123.0, 121.6; HRMS-ESI (m/z): 
[M + H]+ C13H10ONClBr 309.9627; found 309.9629. 
Ethyl (E)-3-(3-((4-chlorophenyl)carbamoyl)phenyl)acrylate 
Palladium(II) acetate (6.8 mg, 0.026 mmol) and tri-
phenylphosphine (7.9 mg, 0.026 mmol) were added to a solution of 
3-bromo-N-(4-chlorophenyl)benzamide (80 mg, 0.259 mmol) in 
DMF (1.0 mL) at room temperature under nitrogen. Ethyl acrylate 
(0.04 mL, 0.259 mmol) and sodium acetate (27 mg, 0.325 mmol) 
were added, and the mixture was heated at 140 ºC for 18 h. After 
cooling to room temperature, water (20 mL/mmol) was added and 
the mixture passed through a pad of Celite. The organic layer was 
extracted with Et2O (3 × 10 mL), separated and washed with water 
(10 mL) and brine (2 × 10 mL) and dried over magnesium sulfate. 
The solvent was concentrated in vacuo to give the crude product. 
Purification by flash chromatography (silica; 0-100% DCM in pet-
rol ether) afforded the title compound as a white solid (25 mg, 
29%).  
Rf 0.14 (100% DCM); mp. 148.7-155.0 ºC; UV λmax (EtOH) 274 
nm; IR νmax 3312, 2981, 2928, 2109, 1703, 1650, 1595, 1535, 1490 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.35 (br s, 1H), 7.94 (s, 1H), 
7.81 (d, J = 8.0 Hz, 1H), 7.64-7.59 (m, 4H), 7.44 (t, J = 8.0 Hz, 1H), 
7.31-7.28 (m, 2H), 6.43 (d, J = 16.0 Hz, 1H), 4.23 (q, J = 7.0 Hz, 
2H), 1.31 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 166.7, 
165.4, 143.2, 136.4, 135.4, 135.1,131.2, 129.8, 129.4, 129.1, 128.6, 
126.6, 121.7, 60.8, 14.3; HRMS-ESI (m/z): [M + H]+ C18H17O3NCl 
330.0888; found 330.0891. 
(E)-3-(3-((4-Chlorophenyl)carbamoyl)phenyl)acrylic acid (38) 
A mixture of ethyl (E)-3-(3-((4-chlorophenyl)carbamoyl)phe-
nyl)acrylate (50 mg, 0.15 mmol), LiOH.H2O, and 
THF:MeOH:H2O (4:2:1, 1 mL) was stirred at 0 ºC for 2 h. The 
mixture was treated with 2M aqueous HCl (2 mL) and extracted 
three times with EtOAc. The combined extracts were dried over 
sodium sulfate, filtered, and concentrated in vacuo to give a white 
solid that was purified by flash column chromatography (silica, 
MeOH: DCM 0:10 to 2:8) to afford 38 (14.4 mg, 31%) as a white 
powder. 
 Rf 0.10 (DCM:MeOH 9:1); m.p. 259-260 ºC; IR νmax 3334, 2919, 
2849, 2633, 2485, 2115, 1719, 1648, 1593, 1522 cm-1; 1H NMR 
(500 MHz, (CD3)2SO) δ 10.44 (1H, s), 8.23 (1H, s), 7.95 (1H, d, J 
= 7.8 Hz), 7.89 (1H, d, J = 7.8 Hz), 7.81 (2H, d, J = 8.8 Hz), 7.66 
(1H, d, J = 16.0 Hz), 7.57 (1H, t, J = 7.8 Hz), 7.42 (2H, d, J = 8.8 
Hz), 6.67 (1H, d, J = 16.0 Hz); 13C NMR (125 MHz, (CD3)2SO) δ 
167.6, 165.2, 143.9, 138.0, 135.3, 134.6, 131.4, 129.4, 129.2 128.6, 
127.5, 126.9, 122.1, 120.9; HRMS-ESI (m/z): [M + H]+ 
C16H13O3N35Cl 302.0579, found 302.0578. 
Ancillary Information 
The Supporting Information is available free of charge on the ACS 
Publications website. Supplementary figures for additional crystal 
structures of 2, 14 and 2-amino-4-trifluoromethylpyridine; ITC 
traces of 1 and 8; crystallographic data table and NMR spectra of 
synthesized compounds. 
All crystallographic results were deposited to and are accessible 
from the Protein Data Bank (PDB) https://www.rcsb.org/. PDB ac-
cession codes for all structures derived from this study are as fol-
lows: 1 6Q3C, 2 6Q3B, 4 6Q3F, 6 6Q49, 7 6Q48, 13 6Q4B, 14 
6Q4A, 16 6Q4C, 31 6Q4D, 32 6Q4F, 33 6Q4E, 34 6Q4J, 35 6Q4I, 
36 6Q4H, 37 6Q4G and 38 6Q4K. 
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